Answers are grounded in this paper and cite their sources.
In summary, these data suggest a promising potential of domatinostat in combination with immunotherapy to improve the outcome of refractory cancer patients.
No takes yet. Share an insight, caveat, or question.
Bretz et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: